Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Butler, 2011, Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells, Sci Transl Med, 3, 80ra34, 10.1126/scitranslmed.3002207 Savoldo, 2006, Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs), Blood, 108, 2942, 10.1182/blood-2006-05-021782 Yee, 2002, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc Natl Acad Sci USA, 99, 16168, 10.1073/pnas.242600099 Walter, 1995, Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor, N Engl J Med, 333, 1038, 10.1056/NEJM199510193331603 Dudley, 2005, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J Clin Oncol, 23, 2346, 10.1200/JCO.2005.00.240 Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842 Robbins, 2011, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1, J Clin Oncol, 29, 917, 10.1200/JCO.2010.32.2537 Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964 Till, 2008, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood, 112, 2261, 10.1182/blood-2007-12-128843 Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 Johnson, 2009, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714 Parkhurst, 2011, T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis, Mol Ther, 19, 620, 10.1038/mt.2010.272 Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol Ther, 18, 843, 10.1038/mt.2010.24 Gilham, 2012, CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe, Trends Mol Med, 18, 377, 10.1016/j.molmed.2012.04.009 Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388 Weijtens, 1996, Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity, J Immunol, 157, 836, 10.4049/jimmunol.157.2.836 Bleumer, 2004, A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients, Br J Cancer, 90, 985, 10.1038/sj.bjc.6601617 Brouwers, 2005, Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma, J Clin Oncol, 23, 6540, 10.1200/JCO.2005.07.732 Steffens, 1999, Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy, Cancer Res, 59, 1615 Steffens, 1999, Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250, Anticancer Res, 19, 1197 Escudier, 2012, Treatment selection in metastatic renal cell carcinoma: expert consensus, Nat Rev Clin Oncol, 9, 327, 10.1038/nrclinonc.2012.59 Lamers, 2011, Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells, Blood, 117, 72, 10.1182/blood-2010-07-294520 Lamers, 2007, Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo, Cancer Immunol Immunother, 56, 1875, 10.1007/s00262-007-0330-3 June, 2012, T-cell therapy at the threshold, Nat Biotechnol, 30, 611, 10.1038/nbt.2305 Coccoris, 2010, T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies, Expert Opin Biol Ther, 10, 547, 10.1517/14712591003614756 Oosterwijk, 1986, Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney, Int J Cancer, 38, 489, 10.1002/ijc.2910380406 Pastoreková, 1997, Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts, Gastroenterology, 112, 398, 10.1053/gast.1997.v112.pm9024293 Straetemans, 2012, T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies, Hum Gene Ther, 23, 187, 10.1089/hum.2010.126 Steffens, 1997, Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250, J Clin Oncol, 15, 1529, 10.1200/JCO.1997.15.4.1529 Brouwers, 2005, Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response, Clin Cancer Res, 11, 7178s, 10.1158/1078-0432.CCR-1004-0010 Divgi, 2004, Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer, J Nucl Med, 45, 1412 Brentjens, 2010, Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial, Mol Ther, 18, 666, 10.1038/mt.2010.31 Caballero, 2009, Cancer/testis (CT) antigens: potential targets for immunotherapy, Cancer Sci, 100, 2014, 10.1111/j.1349-7006.2009.01303.x Lucas, 2000, MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression, Int J Cancer, 87, 55, 10.1002/1097-0215(20000701)87:1<55::AID-IJC8>3.0.CO;2-J Yang, 2007, MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines, Cancer Res, 67, 9954, 10.1158/0008-5472.CAN-07-1478 Straetemans, 2012, TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets, Clin Dev Immunol, 2012, 586314, 10.1155/2012/586314 Davis, 2010, Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials, Clin Cancer Res, 16, 5852, 10.1158/1078-0432.CCR-10-1280 Robbins, 2004, Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy, J Immunol, 173, 7125, 10.4049/jimmunol.173.12.7125 Huang, 2005, Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression, J Immunother, 28, 258, 10.1097/01.cji.0000158855.92792.7a Hawkins, 2010, Development of adoptive cell therapy for cancer: a clinical perspective, Hum Gene Ther, 21, 665, 10.1089/hum.2010.086 Lamers, 2006, Cytotherapy, 8, 542, 10.1080/14653240601056396 Lamers, 2008, Retroviral vectors for clinical immunogene therapy are stable for up to 9 years, Cancer Gene Ther, 15, 268, 10.1038/sj.cgt.7701114 Lamers, 2013, Long-term stability of T cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells, Cytotherapy, 10.1016/j.jcyt.2012.12.006 Lamers, 2002, Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer, Cancer Gene Ther, 9, 613, 10.1038/sj.cgt.7700477 Lamers, 2006, Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer, Cancer Gene Ther, 13, 503, 10.1038/sj.cgt.7700916 Canevari, 1995, Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody, J Natl Cancer Inst, 87, 1463, 10.1093/jnci/87.19.1463 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Steffens, 1999, Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250, Clin Cancer Res, 5, 3268s Grabmaier, 2000, Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250, Int J Cancer, 85, 865, 10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q Uemura, 1994, Internal image antiidiotype antibodies related to renal-cell carcinoma-associated antigen G250, Int J Cancer, 56, 609-614, 10.1002/ijc.2910560424 Lamers, 2005, Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression, Hum Gene Ther, 16, 1452, 10.1089/hum.2005.16.1452